BPRO yields 9.01% · PFE yields 6.13%● Live data
📍 PFE pulled ahead of the other in Year 10
Combined, BPRO + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of BPRO + PFE for your $10,000?
BPRO seeks capital appreciation by investing in assets resilient to currency debasement, or the decline in major currencies value or purchasing power. Debasement-resistant assets (considered difficult to inflate or manipulate) include gold and other precious metals, as well as digital assets such as Bitcoin. The Fund invests in ETPs holding these assets and in ETFs with exposure to precious metal miners. Investments may include equity or debt securities issued by relevant companies, as well as sovereign debt, global currencies, and structured products or geared ETPs linked to these asset classes. Investments are not fixed, and selection utilizes macroeconomic views and proprietary modeling, which is reviewed at least weekly. The actively managed fund is expected to have significant gold exposure and does not invest directly in cryptocurrency. BPRO may use options contracts, taking different positions based on expected price movements of the underlying assets.
Full BPRO Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.